Gregory A. Demopulos,Thomas Dudler,Hans-Wilhelm Schwaeble
申请号:
US16509336
公开号:
US20200157244A1
申请日:
2019.07.11
申请国别(地区):
US
年份:
2020
代理人:
摘要:
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.